This HTML5 document contains 116 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q58847619
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel artículu científicu espublizáu en setiembre de 2010 наукова стаття, опублікована у вересні 2010 scientific article published on 22 September 2010 im September 2010 veröffentlichter wissenschaftlicher Artikel
p:P577
wds:Q58847619-BAA52AB1-9AAA-461D-9C3E-BF2FFC98205F
wdt:P577
2010-09-22T00:00:00Z
p:P2860
wds:Q58847619-7473D916-5F7C-4462-8E38-DBEF8E1D2945 wds:Q58847619-1D1AB666-0408-4B6F-9005-A592AD29FD93 wds:Q58847619-201B3C89-6BA0-4190-BDA3-C0A9666C53B1 wds:Q58847619-2066BA92-1C31-4B1D-92B8-8EE97B3B7B14 wds:Q58847619-0E58F001-B27F-4182-A32C-E71AE0B1EE0E wds:Q58847619-100E1097-F67A-47DD-8407-DE10CD7AC40C wds:Q58847619-1A69C20B-F2FA-4F9C-813A-5F483A2976F0 wds:Q58847619-30A4FA15-FC73-425E-A650-BE0FC5CF3AAD wds:Q58847619-33D68656-DFC8-459F-8D26-E8693E0D1D48 wds:Q58847619-29AA7B6E-3E0E-48D5-A9FC-FA4266CF5268 wds:Q58847619-2C50F34C-69BF-43DB-94FC-0C256A554197 wds:Q58847619-00767C5D-2E1D-488E-B4FA-6E05B47D0A9A wds:Q58847619-FC24AFA1-8CD8-487E-83F2-03DE29CE0422 wds:Q58847619-9E64BCFC-AD9B-444D-9783-33ACE232DE18 wds:Q58847619-A2825431-DE2F-4A10-B471-02665E9504A1 wds:Q58847619-85490044-BE6B-43FD-AF86-89D4A8E1DA11 wds:Q58847619-89B0DE4F-B965-4746-ABC3-77648F9F734E wds:Q58847619-EBA8462E-4721-40B4-AC94-D2994FB6369E wds:Q58847619-EC324770-E1F4-4AAC-934B-A4B367CD59F9 wds:Q58847619-D0DD076C-3598-4021-995F-B2140328E78A wds:Q58847619-D2938CE5-B4AB-4FC0-8404-130D87A50754 wds:Q58847619-58BC88A6-1F8B-453C-80AB-59319A1B1779 wds:Q58847619-58DC930D-E3F0-4B8E-92CC-6238403AA1F6 wds:Q58847619-4841C4DF-45B8-43CC-9409-FDA3909E7133 wds:Q58847619-48DBBDC7-C0AA-4517-BC50-D922340B47B6 wds:Q58847619-4FF80A41-DD55-484D-B61D-8EDB12A7C5E7 wds:Q58847619-7C6EFAF0-1A90-49E2-A2FF-A9CE6516455D wds:Q58847619-7E3C81B3-4116-42A8-A596-1012CF2EA0CC wds:Q58847619-6A08393A-B98B-47DD-BA7F-4095CB48AA74 wds:Q58847619-6B745736-525B-423A-980F-FB96A90BAF4B
wdt:P2860
wd:Q46876178 wd:Q37403023 wd:Q94507905 wd:Q46974546 wd:Q80396416 wd:Q33997854 wd:Q57571430 wd:Q46728938 wd:Q35599092 wd:Q36426847 wd:Q48854744 wd:Q34657509 wd:Q34621382 wd:Q73857203 wd:Q46214355 wd:Q53718715 wd:Q80796158 wd:Q35740647 wd:Q82871045 wd:Q33336718 wd:Q46583056 wd:Q34491437 wd:Q47922337 wd:Q37593059 wd:Q57217547 wd:Q37163550 wd:Q37098098 wd:Q77398448 wd:Q34788452 wd:Q46930590
p:P2093
wds:Q58847619-198A98D8-7B8F-4DD9-8367-3D223425FEF7 wds:Q58847619-276131E2-FF79-46C2-AFD9-58F974B906D7 wds:Q58847619-28D96C34-78C3-4273-8C4F-4D0441B9B035 wds:Q58847619-3988BDCE-DCF7-4651-A29B-EE5CCA26B071 wds:Q58847619-5ECE3A5D-BA1E-4AFE-A981-37A43EC5D72F wds:Q58847619-C76159ED-D354-4B75-9C81-4488F6C658C8 wds:Q58847619-E125E358-A30A-4D3D-8CC3-9D200E3A5B84
wdt:P2093
Maria do Carmo P Nunes Eric Boersma Márcia M Barbosa Marcel L Geleijnse Milena S Marcolino Maria Helena C R Silva Nelma C D Clementino
rdfs:label
The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients
skos:prefLabel
The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients
schema:name
The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients
p:P50
wds:Q58847619-7B31CB61-DE7E-4700-A8F7-B60AFA6CA430
wdt:P50
wd:Q46583120
p:P1476
wds:Q58847619-FA2581DD-F260-40D5-9D5F-E06EB5D9E1FD
wdt:P1476
The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients
p:P304
wds:Q58847619-1C1597CD-2728-48A7-B052-2638F22C1D95
wdt:P304
124-130
p:P31
wds:Q58847619-ECB55325-AB49-46D6-8D2F-F8EBEE3D3E53
wdt:P31
wd:Q13442814
p:P921
wds:Q58847619-7A646284-EBDE-4AD4-9D23-AF19049F9745 wds:Q58847619-50E0870C-6EC0-429A-BE2D-EC0A97862F20 wds:Q58847619-87DAEDF8-3DA5-42E0-844A-DFF7392DD1C3 wds:Q58847619-9ADD8460-C99A-4ED7-A156-DFC7B639E9B0
wdt:P921
wd:Q177094 wd:Q103824 wd:Q3421914 wd:Q29496
p:P698
wds:Q58847619-3313EF65-1A2E-48D6-9733-70F9B7C78A81
wdtn:P698
n10:20860069
wdt:P698
20860069
p:P1433
wds:Q58847619-D4D61FAE-8D2D-4A44-B0D2-E7FBDDE43454
wdt:P1433
wd:Q15762617
p:P433
wds:Q58847619-E78ADC82-7180-46D4-9920-E80CDF70AB11
p:P478
wds:Q58847619-4EF87DA8-914C-4EDC-9CD6-8BF48DA35695
wdt:P433
3
wdt:P478
29
p:P356
wds:Q58847619-82A6D6C4-44C2-46C2-AB59-BEA09120F3C8
wdtn:P356
n12:HON.967
wdt:P356
10.1002/HON.967